To conclude, under hypoxia, which is an important feature of CRC tumors and a main mechanism of therapy resistance, the apparently rational approach of combining ABT-737 for inhibition of anti-apoptotic proteins with the mTOR inhibitor AZD8055 [9] in CRC cell lines with co-occurring KRAS and PIK3CA mutations revealed complex responses of pro-survival effects elicited in parallel with apoptosis. This evidence concerns the gene PIK3CA and colorectal carcinoma.